A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
Status:
Completed
Trial end date:
2021-05-06
Target enrollment:
Participant gender:
Summary
A Phase 2 study with 4 treatment groups of two differing doses and matched placebos designed
to evaluate the safety (including hepatic safety), tolerability and pharmacodynamic effects
of two dose levels of MEDI0382 in obese subjects with non-alcoholic fatty liver disease
(NAFLD)/non-alcoholic steatohepatitis (NASH). The subjects will have biopsy-confirmed
NAFLD/NASH with liver fibrosis stage F1, F2 or F3. Approximately 72 subjects will be
randomized